Ibrutinib and Indolent B-Cell Lymphomas

Overview of attention for article published in Clinical Lymphoma, Myeloma & Leukemia, November 2013

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 1 X user

patent: 5 patents

Readers on

mendeley: 47 Mendeley

So far, Altmetric has seen 5 patents that reference this research output.

Cerdulatinib for the treatment of b-cell malignancies

Grant US-12350269-B2

United States of America

08 Jul 2025

Solid forms of Cerdulatinib

Grant US-11713309-B2

United States of America

01 Aug 2023

Cerdulatinib for treating hematological cancers

Grant US-11446300-B2

United States of America

20 Sep 2022

Solid forms of cerdulatinib

Grant US-10865198-B2

United States of America

15 Dec 2020

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 1 additional patents.